Skip to main content

Efficient Laboratory Workflow Management

BayBiotech.NET

In current times demands on laboratory performance are becoming more intensive as the number of new tests and diseases are adding on to our list as well as a greater demand for accuracy in test results is increasing by a much more controlled regulatory environment.
In order to meet these demands, laboratory personnel are working on an ongoing basis to improve efficiency and productivity through better control over the operation and function of all aspects of the testing process by incorporating automation and use of computerized system wherever possible.

Creation of an efficient Workflow
helps make the entire process cost effective and efficient and a framework for creating a workflow may include:
1. Understanding the issues relating to creating a work list
2. Describe ways to minimize laboratory contamination
3. Understand ways to improve labor efficiency
4. Understand key variables that contribute to testing accuracy
 Explain the importance of sensitivity and specificity
 Describe the relationship between prevalence and predictive value

The core of a good laboratory set-up must focus on providing the practitioner with accurate test results that can be achieved by minimizing the cross-contamination and avoiding loss of in-process test samples at different steps of the test performed.

Two main types of cross-contamination that can occur in a laboratory set-up are:

 Organism contamination from the original sample
 Amplicon contamination, which can occur when aerosols from the amplified product enter the air and ultimately transfer to other sample tubes. Trace amounts of amplicon can initiate additional amplification reactions, potentially leading to false-positive results

Benefits of Automation:

In order to minimize the errors and maximize the accuracy of a test result organizations are implementing automations and the benefits of it include:
 Efficiency gains
 Improved turnaround time (TAT)
 Reduction in laboratory errors
 Overall improvement in patient care

In order to avoid the cross-contamination, the Laboratory design considerations may include:

1. A secluded area for sample preparation. Identify key variables that affect specimen collection and transport.
2. Describe the steps in a sample collection procedure.
3. Define carry-over contamination and describe methods to prevent its occurrence.
4. Describe methods for minimizing sample inhibition.
5. Identify sample preparation procedures that increase the risk of contamination.

In order to avoid the cross-contamination, the laboratory routine process may include:

 Avoiding moving freshly filled pipettes tips over open tubes.
 Use pipette tips that have aerosol plugs.
 Maintain physical separation between preamplified materials and amplified.
 Incorporate barriers such as oil or covers in the amplification reaction mix.
 Follow manufacturer's procedures for daily cleaning and decontamination.
 Identify sources of physical contamination, such as frequent touch-points on workstations, keyboards, telephones, etc.
 Change gloves frequently.
 Change lab coats frequently or utilize disposable gowns.
 Restrict gowns and equipment to single areas.
 Perform laboratory environmental "swipe" tests routinely to check for contamination.
Implement routine monitoring of technologist procedures to ensure strict compliance. To read more on this visit:

http://www.lab-education.org/review_ed_mod/mod01_slide38.htm

Comments

Popular posts from this blog

Group C (Treatment IND) Drugs

BayBiotech.NET Since 1976, National Cancer Institute (NCI) in agreement with FDA has established the Group C classification system to allow access to certain drugs for the cancer patients specifically falling under a category that adequate alternative therapy or if the available alternative therapy has significant toxic effects. Each Group C drug protocol specifies patient eligibility and drug use information. Group C drugs are provided only to properly trained physicians who have registered themselves with NCI using a special form to assure that their patient qualifies under guidelines - or protocols - for the drug. Physicians using drugs under Group C have no reporting requirements to the NCI other than the obligation to report adverse drug reactions. Group C drugs are provided free of charge, and the Centers for Medicare and Medicaid Services provides coverage for care associated with Group C therapy. Making Group C drugs available to the critically ill patients not only provi...

Good Machine Learning Practices

BayBiotech.NET A joint effort by FDA,  United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada have developed guiding principles to help promote utilization of medical devices that are safe and effective and utilize artiificial intelligence and machine learning. To find out more details check out the link here!

A New Clinical Trial Platform

BayBiotech.NET The Medpedia Project has established a platform ‘Medpedia Clinical Trials’ for patients, researchers and physicians to receive information about the thousands of clinical trials that are in process or about to begin worldwide. The information on various clinical trials is updated regularly from ClinicalTrials.gov and can be searched using different attributes with basic and advanced search functionalities. Medpedia Clinical Trials platform allows visitors to leave their comments, thoughts and views on a specific clinical trial page. Most importantly, a personalized feed can also be obtained if someone is interested in learning more about on-going or about to start clinical trials on a particular condition worldwide. Moreover, if you are reading a Medpedia article on a particular clinical condition, the information on the related clinical trials are fed automatically alongside the article page. To learn more about it visit http://www.medpedia.com/clinical-trials .